The Pediatric HIV/AIDS Cohort Study (PHACS) was created in 2005 to evaluate the clinical course of perinatally acquired HIV infection among adolescents and pre-adolescents and the consequences of fetal and neonatal exposure to HIV and antiretroviral chemotherapy among a representative cohort of children in the United States. A cohort of 450 perinatally infected adolescents and preadolescents (Adolescent Master Protocol, AMP, age 7-16 at enrollment) was established to evaluate the impact of HIV and ART on sexual maturation, pubertal development, and socialization;and, a drug toxicity surveillance system (Surveillance Monitoring for Anti-Retroviral Toxicities Study (SMARTT) enrolled 1,934 perinatally HIV exposed uninfected children to evaluate long-term effects of in-utero ART exposure. PHACS is comprised of a Scientific Leadership Group (SLG), which is overseen by a Coordinating Center, a Data and Operations Center (DOC), and 24 clinical sites. The Department of Epidemiology and the Center for Biostatistics in AIDS Research (CBAR) at the Harvard School of Public Health, Westat, and the Frontier Science Foundation collaborate to form the PHACS DOC. The DOC collaborates with the SLG to define the PHACS research agenda;provides methodological support for the development of all PHACS analytic projects;merges data from pre-existing databases from previous cohorts (PACTG 219/219C, WITS, Legacy);maintains clinical site subcontracts and trains and monitors sites in proper procedures for PHACS research;plans and conducts all leadership and full PHACS network meetings;and, supports an active CAB. In PHACS II, the DOC will continue the duties described above while refining its practices, as well as follow and enroll an additional 1,200-1,500 children into SMARTT. Together, HSPH, Westat and Frontier Science bring long histories of providing the type of methodologic and operational support required by PHACS, as well as innovative methods to enhance and maximize the efficiency of PHACS study design, conduct, and analysis. Given our prior and current professional experience, we are uniquely positioned to provide the scientific/epidemiologic and operational leadership to successfully conduct PHACS.

Public Health Relevance

The activities described in this application are relevant to public health in that they will provide public health professionals with an increased understanding of the risks of antiretroviral use in the prenatal period and the affects of HIV on the development of youth and adolescents. This increased understanding can subsequently translate into improved prevention and treatment services for families affected by HIV/AIDS.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Research Project--Cooperative Agreements (U01)
Project #
2U01HD052102-06
Application #
7982339
Study Section
Special Emphasis Panel (ZHD1-DSR-A (06))
Program Officer
Shirazi, Yasaman
Project Start
2005-09-30
Project End
2015-07-31
Budget Start
2010-09-18
Budget End
2011-07-31
Support Year
6
Fiscal Year
2010
Total Cost
$16,140,000
Indirect Cost
Name
Harvard University
Department
Public Health & Prev Medicine
Type
Schools of Public Health
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code
02115
Lipshultz, Steven E (2018) Letter by Lipshultz Regarding Article, ""Anthracycline Cardiotoxicity: Worrisome Enough to Have You Quaking?"" Circ Res 122:e62-e63
Alperen, Julie; Davidson, Julie; Siminski, Suzanne et al. (2018) Utility of the National Death Index in Identifying Deaths in a Clinic-Based, Multisite Cohort: The Experience of the Pediatric HIV/AIDS Cohort Study. J Acquir Immune Defic Syndr 79:e37-e39
Garvie, Patricia A; Nichols, Sharon L; Williams, Paige L et al. (2018) Development and reliability of the Prospective Memory Assessment for Children & Youth (PROMACY): A preliminary study in a nonclinical sample. Appl Neuropsychol Child :1-14
Geffner, Mitchell E; Patel, Kunjal; Jacobson, Denise L et al. (2018) Changes in insulin sensitivity over time and associated factors in HIV-infected adolescents. AIDS 32:613-622
Williams, Paige L; Huo, Yanling; Rutstein, Richard et al. (2018) Trends in Neonatal Prophylaxis and Predictors of Combination Antiretroviral Prophylaxis in US Infants from 1990 to 2015. AIDS Patient Care STDS 32:48-57
Correia, Katharine; Williams, Paige L (2018) Estimating the Relative Excess Risk Due to Interaction in Clustered-Data Settings. Am J Epidemiol 187:2470-2480
Williams, Paige L; Jesson, Julie (2018) Growth and pubertal development in HIV-infected adolescents. Curr Opin HIV AIDS 13:179-186
Innes, Steve; Patel, Kunjal (2018) Noncommunicable diseases in adolescents with perinatally acquired HIV-1 infection in high-income and low-income settings. Curr Opin HIV AIDS 13:187-195
Rice, Mabel L; Russell, Jonathan S; Frederick, Toni et al. (2018) Risk for Speech and Language Impairments in Preschool Age HIV-exposed Uninfected Children With In Utero Combination Antiretroviral Exposure. Pediatr Infect Dis J 37:678-685
Williams, Paige L; Correia, Katharine; Karalius, Brad et al. (2018) Cardiac status of perinatally HIV-infected children: assessing combination antiretroviral regimens in observational studies. AIDS 32:2337-2346

Showing the most recent 10 out of 143 publications